Clinical studies so far with the anti-EpCAM mAbs for cancer therapy showed only the low success with limited anti-tumor effects, which highlights the need for the development of more efficacious anti-EpCAM antibody drug candidates. The gene discussed is EPCAM; the disease is neoplasm.